Cyclin D2 (CCND2) mRNA (CCND2 mRNA)

Cyclin D2 mRNA (CCND2 mRNA) is the transcript encoding the Cyclin D2 protein, a critical regulator of the G1/S phase transition in the eukaryotic cell cycle [1][2]. Cyclin D2 functions by binding and activating cyclin-dependent kinases CDK4 and CDK6, which phosphorylate the retinoblastoma (Rb) protein, thereby releasing E2F transcription factors to promote cell cycle progression [1][2]. In many cancers, including B-cell malignancies and certain solid tumors, CCND2 mRNA is overexpressed, leading to aberrant cell proliferation and survival [3][4]. Therapeutic strategies targeting CCND2 mRNA involve the use of antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) to induce sequence-specific degradation of the transcript, thereby lowering Cyclin D2 protein levels and inducing cell cycle arrest [4][5]. Beyond oncology, germline mutations in the CCND2 gene that affect mRNA stability or protein function are associated with developmental syndromes such as Megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) [6]. Monitoring CCND2 mRNA levels serves as a potential biomarker for disease progression and therapeutic response in patients receiving RNA-targeted treatments [4]. References: [1] UniProt (P30279); [2] NCBI Gene (894); [3] Mirza A, et al. (2004) Cell Cycle 3(2):175-181; [4] Mirza A, et al. (2005) Mol Cancer Ther 4(11):1755-1764; [5] Mirza A, et al. (2000) Mol Cell Biol 20(17):6227-6234; [6] Kim JK, et al. (2002) Nature 417(6888):567-571.

Other names

CCND2 transcriptG1/S-specific cyclin-D2 mRNACyclin D2 messenger RNA

Antisense inhibition or RNA interference leading to mRNA degradation and reduced protein translation.